scholarly journals Potential adverse effects of cyclosporin A on kidneys after spinal cord injury

Spinal Cord ◽  
2010 ◽  
Vol 49 (3) ◽  
pp. 472-479 ◽  
Author(s):  
N Lonjon ◽  
G Boniface ◽  
R Feifel ◽  
R Endres ◽  
M Gimenez y Ribotta ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Adverse Effects ◽  
Cyclosporin A ◽  
Cord Injury

Unwanted Muscle Weakness following Botulinum Neurotoxin A Administration in Spinal Cord Injury with Literature Review

2012 ◽  
Vol 23 (1) ◽  
pp. 20-24
Author(s):  
Tapan N Joshi
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Adverse Effects ◽  
Muscle Weakness ◽  
Botulinum Neurotoxin ◽  
Adult Population ◽  
Functional Decline ◽  
High Dose ◽  
Botulinum Neurotoxin A ◽  
Cord Injury

Abstract Botulinum neurotoxin A (BoNTA) is rapidly gaining acceptance for management of spasticity secondary to spinal cord injury (SCI). Due to its increased usage, more undesirable effects and complications have come in light. Unwanted distant and/or generalised muscle weakness is possible following BoNTA administration in SCI population causing temporary neurological and functional decline. Physicians should carefuly perform a clinical assessment of every patient individually for risks stratification. Additional studies for adult population evaluating adverse-effects of high dose of BoNTA treatment for spasticity management are indicated.

Cyclosporin A Treatment Following Spinal Cord Injury to the Rat: Behavioral Effects and Stereological Assessment of Tissue Sparing

2001 ◽  
Vol 18 (5) ◽  
pp. 513-522 ◽  
Author(s):  
Alexander G. Rabchevsky ◽  
Isabella Fugaccia ◽  
Patrick G. Sullivan ◽  
Stephen W. Scheff
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Cyclosporin A ◽  
Behavioral Effects ◽  
Cord Injury ◽  
Tissue Sparing

The Effects of Cyclosporin A and Insulin on Ischemic Spinal Cord Injury in Rabbits

2006 ◽  
Vol 102 (6) ◽  
pp. 1722-1727 ◽  
Author(s):  
Shunsuke Tsuruta ◽  
Mishiya Matsumoto ◽  
Shiro Fukuda ◽  
Atsuo Yamashita ◽  
Ying Jun Cui ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Cyclosporin A ◽  
Cord Injury ◽  
Ischemic Spinal Cord Injury

Intrathecal Baclofen for Severe Spasticity Secondary to Spinal Cord Injury

1993 ◽  
Vol 27 (6) ◽  
pp. 767-774 ◽  
Author(s):  
Kelly S. Lewis ◽  
Wade M. Mueller
Keyword(s):  
Spinal Cord ◽  
Central Nervous System ◽  
Spinal Cord Injury ◽  
Nervous System ◽  
Adverse Effects ◽  
Intrathecal Baclofen ◽  
Clinical Effects ◽  
Spinal Cord Trauma ◽  
Open Label ◽  
Cord Injury

OBJECTIVE: To evaluate the use of intrathecal baclofen for the treatment of muscle spasticity in patients with spinal cord injury. DATA SOURCES: A MEDLINE search was used to identify relevant and pertinent literature. Information was obtained from open-label clinical trials, abstracts, conference proceedings, and review articles. Index terms in the search included baclofen, spasticity, intrathecal drug infusion, spinal cord disease, and neurosurgery. DATA EXTRACTION: Studies were selected for review if they evaluated intrathecal baclofen in patients with spinal cord injury. Emphasis was placed on human studies published in the English language. Trials were reviewed by dosage regimen, therapeutic response, adverse effects, and complications. DATA SYNTHESIS: Thus far, intrathecal baclofen administration shows promise in the treatment of spasticity resulting from spinal cord trauma. Few complications and adverse effects have been reported. CONCLUSIONS: Muscle spasms and spasticity constitute a significant problem in spinal cord injuries, interfering with rehabilitation and leading to inconveniences and complications in these patients. Oral baclofen is the drug of choice for spasticity due to spinal cord trauma. It often is ineffective, however, because of the large dosages required to cross the blood-brain barrier and the subsequent appearance of central nervous system adverse effects. These adverse effects are not tolerated by many patients. Intrathecally administered baclofen has been approved by the Food and Drug Administration (FDA) for the treatment of spasticity in patients with spinal cord injury who are refractory to or cannot tolerate oral baclofen. It is intended for use only in implantable pumps approved by the FDA for the administration of baclofen into the intrathecal space. Intrathecal administration achieves high concentrations in the spinal cord with small dosages, thus reducing the incidence of central nervous system adverse effects. To date, approximately 350 patients with spinal cord injury have been treated with intrathecal baclofen. Reductions in spasticity have been demonstrated in both open-label and placebo-controlled trials. Patients also often make substantial gains in activities of daily living. Few adverse effects and complications have been reported. However, tolerance to the clinical effects of intrathecal baclofen has been reported. Further studies are needed to determine specific patient populations that may benefit most from intrathecal baclofen administration. Individual dosage ranges and follow-up care also need to be defined more completely. In addition, the question of whether tolerance detracts from long-term clinical benefits with intrathecal baclofen needs to be addressed.

scholarly journals Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury

2017 ◽  
Vol 34 (6) ◽  
pp. 1164-1174 ◽  
Author(s):  
Miriam Aceves ◽  
Eric A. Bancroft ◽  
Alejandro R. Aceves ◽  
Michelle A. Hook
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Adverse Effects ◽  
Cord Injury

Midodrine: Insidious development of urologic adverse effects in patients with spinal cord injury: A report of 2 cases

2007 ◽  
Vol 24 (4) ◽  
pp. 712-720 ◽  
Author(s):  
Subramanian Vaidyanathan ◽  
Bakul M. Soni ◽  
Peter L. Hughes
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Adverse Effects ◽  
Cord Injury ◽  
Insidious Development

Do cyclosporin A and insulin synergistically protect against ischemic spinal cord injury in rabbits?

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S33-S33
Author(s):  
Shyunsuke Tsuruta ◽  
Mishiya Matsumoto ◽  
Yumika Koizumi ◽  
Shiro Fukuda ◽  
Takefumi Sakabe
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Cyclosporin A ◽  
Cord Injury ◽  
Ischemic Spinal Cord Injury
Sign in / Sign up

Export Citation Format

Share Document